StonvexLoading…
StonvexStonvexStonvexCore line items from CBT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Q4 2025 2025-12-31 | Annual 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $1.75B | $849.00M | $3.71B | $2.81B |
Operating Income | $258.00M | $129.00M | $621.00M | $484.00M |
Net Income | $141.00M | $73.00M | $331.00M | $288.00M |
EPS (Diluted) | $2.64 | $1.37 | $6.02 | $5.22 |
Total Assets | $3.90B | $3.76B | $3.81B | $3.84B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $252.00M | $230.00M | $258.00M | $239.00M |
Free Cash Flow OCF − CapEx | $89.00M | $57.00M | $391.00M | $236.00M |
Shares Outstanding | 51.58M | 52.22M | 52.84M | 53.20M |